Salarius Pharmaceuticals, Inc.
3.8625+0.01 (+0.33%)
Oct 30, 9:37:24 AM EDT · NasdaqCM · SLRX · USD
Key Stats
Market Cap
4.06MP/E (TTM)
-Basic EPS (TTM)
-23.70Dividend Yield
0%Recent Filings
8-K
Merger bonus approved
Salarius Pharmaceuticals approved a $225,000 cash transaction bonus for Acting CEO and CFO Mark J. Rosenblum on October 21, 2025, payable upon closing the merger with Decoy Therapeutics, provided he remains employed through that date. This incentive aligns leadership with the ongoing merger process, amended multiple times since January. Bonus ties directly to deal success. Yet the closing timeline remains undisclosed.
8-K
Regains Nasdaq equity compliance
Salarius Pharmaceuticals regained compliance with Nasdaq's minimum stockholders' equity rule on October 10, 2025, following its earlier bid price recovery, putting it fully in line with listing standards amid its planned merger with Decoy Therapeutics. The deal, announced January 13, 2025, will rebrand the entity as Decoy and integrate Salarius' SP-3164 into peptide-based PROTACs, while advancing Decoy's pipeline toward an IND filing for a pan-coronavirus antiviral within 12 months. Yet a one-year monitor looms. Non-compliance could trigger delisting.
8-K
Salarius boosts equity via stock sales
Salarius Pharmaceuticals raised $6.2 million through recent stock sales—$2.4 million from 434,882 shares via an at-the-market offering and $3.8 million from 367,887 shares to C/M Capital Master Fund—pushing stockholders' equity above Nasdaq's $2.5 million threshold as of October 6, 2025. This move aims to secure continued listing on the Nasdaq Capital Market by the October 20 deadline. Equity now exceeds the minimum. Yet Nasdaq's final confirmation remains pending, with preliminary figures subject to quarter-end adjustments.
8-K
Merger amendment refines stock terms
Salarius Pharmaceuticals amended its merger agreement with Decoy Therapeutics on September 17, 2025, via a Fifth Amendment that tweaks conversion terms for Series A and B Preferred Stock. It sets a $10.50 baseline issuance price for adjustments in dilutive financings, with a $3.75 floor, while boosting Series B redemption to that price times 1,000. This sharpens investor protections amid the pending deal. Yet risks linger if financings dilute shares further.
8-K
Regains Nasdaq bid compliance
Salarius Pharmaceuticals regained Nasdaq compliance with the minimum bid price rule on September 4, 2025, after its stock held above $1.00 for 10 straight business days. Yet it still falls short on the equity standard, with a deadline of October 20, 2025, to fix that. A one-year monitor looms if prices dip again. Merger with Decoy Therapeutics advances, eyeing pipeline boosts in antivirals and oncology.
IPO
Employees
Sector
Industry
ALXO
ALX Oncology Holdings Inc.
1.59+0.05
AURA
Aura Biosciences, Inc.
6.14-0.23
CNSP
CNS Pharmaceuticals, Inc.
7.60-0.71
LIMN
Liminatus Pharma, Inc.
1.42+0.00
LIXT
Lixte Biotechnology Holdings, I
4.35+0.07
MNPR
Monopar Therapeutics Inc.
84.16+4.24
NRIX
Nurix Therapeutics, Inc.
11.70-0.20
SLXN
Silexion Therapeutics Corp
3.44+0.01
TNGX
Tango Therapeutics, Inc.
7.83+0.04
XLO
Xilio Therapeutics, Inc.
0.81-0.01